These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22526021)

  • 1. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.
    Hart MP; Brettschneider J; Lee VM; Trojanowski JQ; Gitler AD
    Acta Neuropathol; 2012 Aug; 124(2):221-30. PubMed ID: 22526021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
    Hart MP; Gitler AD
    J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
    Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
    Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
    Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
    Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
    Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
    Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.
    McGurk L; Lee VM; Trojanowksi JQ; Van Deerlin VM; Lee EB; Bonini NM
    J Neuropathol Exp Neurol; 2014 Sep; 73(9):837-45. PubMed ID: 25111021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
    van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
    Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.
    Conforti FL; Spataro R; Sproviero W; Mazzei R; Cavalcanti F; Condino F; Simone IL; Logroscino G; Patitucci A; Magariello A; Muglia M; Rodolico C; Valentino P; Bono F; Colletti T; Monsurrò MR; Gambardella A; La Bella V
    Neurology; 2012 Dec; 79(24):2315-20. PubMed ID: 23197749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
    Elden AC; Kim HJ; Hart MP; Chen-Plotkin AS; Johnson BS; Fang X; Armakola M; Geser F; Greene R; Lu MM; Padmanabhan A; Clay-Falcone D; McCluskey L; Elman L; Juhr D; Gruber PJ; Rüb U; Auburger G; Trojanowski JQ; Lee VM; Van Deerlin VM; Bonini NM; Gitler AD
    Nature; 2010 Aug; 466(7310):1069-75. PubMed ID: 20740007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS.
    Bonini NM; Gitler AD
    J Mol Neurosci; 2011 Nov; 45(3):676-83. PubMed ID: 21660502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
    Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
    Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
    Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
    PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.
    Brettschneider J; Van Deerlin VM; Robinson JL; Kwong L; Lee EB; Ali YO; Safren N; Monteiro MJ; Toledo JB; Elman L; McCluskey L; Irwin DJ; Grossman M; Molina-Porcel L; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2012 Jun; 123(6):825-39. PubMed ID: 22426854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis.
    Sanelli T; Xiao S; Horne P; Bilbao J; Zinman L; Robertson J
    J Neuropathol Exp Neurol; 2007 Dec; 66(12):1147-53. PubMed ID: 18090923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
    Gispert S; Kurz A; Waibel S; Bauer P; Liepelt I; Geisen C; Gitler AD; Becker T; Weber M; Berg D; Andersen PM; Krüger R; Riess O; Ludolph AC; Auburger G
    Neurobiol Dis; 2012 Jan; 45(1):356-61. PubMed ID: 21889984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.
    Figley MD; Thomas A; Gitler AD
    Neurobiol Aging; 2014 Apr; 35(4):936.e1-4. PubMed ID: 24269018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis.
    Toyoshima Y; Takahashi H
    Neuropathology; 2014 Feb; 34(1):77-82. PubMed ID: 23889603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion.
    Bäumer D; East SZ; Tseu B; Zeman A; Hilton D; Talbot K; Ansorge O
    Acta Neuropathol; 2014 Oct; 128(4):597-604. PubMed ID: 24718895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia.
    Mori F; Tanji K; Zhang HX; Nishihira Y; Tan CF; Takahashi H; Wakabayashi K
    Acta Neuropathol; 2008 Aug; 116(2):193-203. PubMed ID: 18560845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.